Evgeny N Imyanitov1,2,3,4, Irina A Demidova5, Marat G Gordiev6, Maxim L Filipenko7, Tatyana V Kekeyeva8, Yuri K Moliaka9, Polina A Gervas10, Valeriy B Kozhemyako11, Dmitriy I Vodolazhskiy12, Liubov A Sergeyeva13, Dinara U Fattakhova14, Aglaya G Iyevleva15,16, Natalia V Mitiushkina15, Ekatherina Sh Kuligina15, Alexey A Barinov5, Meriiam S Mommaeva6, Svetlana N Aleksakhina15,17, Ilya V Tsimafeyeu18, Sergey A Tjulandin19. 1. N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia. evgeny@imyanitov.spb.ru. 2. St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia. evgeny@imyanitov.spb.ru. 3. I.I. Mechnikov North-Western Medical University, St.-Petersburg, 191015, Russia. evgeny@imyanitov.spb.ru. 4. St.-Petersburg State University, St.-Petersburg, 199034, Russia. evgeny@imyanitov.spb.ru. 5. City Oncological Hospital No 62, Moscow, 143423, Russia. 6. Tatarstan Cancer Center, Kazan, 420029, Russia. 7. Institute of Chemical Biology and Fundamental Medicine, Novosibirsk, 630090, Russia. 8. Research Center of Medical Genetics, Moscow, 115478, Russia. 9. Regional Oncological Hospital, Krasnodar, 350051, Russia. 10. Tomsk Cancer Research Institute, Tomsk, 634028, Russia. 11. Pacific Institute of Bioorganic Chemistry, Vladivostok, 690022, Russia. 12. Institute of Oncology, Rostov, 344037, Russia. 13. Regional Oncological Hospital, Ekaterinburg, 620000, Russia. 14. Oncological Hospital of the Republic of Bashkortostan, Ufa, 450054, Russia. 15. N.N. Petrov Institute of Oncology, St.-Petersburg, 197758, Russia. 16. St.-Petersburg Pediatric Medical University, St.-Petersburg, 194100, Russia. 17. St.-Petersburg State University, St.-Petersburg, 199034, Russia. 18. Russian Society of Clinical Oncology (RUSSCO), Moscow, 127051, Russia. 19. N.N. Blokhin Cancer Center, Moscow, 115478, Russia.
Abstract
INTRODUCTION: This study was aimed to evaluate distribution of epidermal growth factor receptor (EGFR) mutations in a large series of Russian lung cancer (LC) patients. METHODS: 10,607 LC samples were considered for EGFR analysis; EGFR status was successfully determined in 10,426 cases (98.3 %), indicating relatively low failure rate. RESULTS: EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas. The occurrence of EGFR mutations in adenocarcinomas gradually increased with age, being attributed mainly to the increment of the L858R frequency in non-smokers (patients aged 18-30 years: 1/27 (3.7 %); 31-40 years: 5/98 (5.1 %); 41-50 years: 18/276 (6.5 %); 51-60 years: 102/944 (10.8 %); 61-70 years: 138/1011 (13.7 %); 71-80 years: 85/496 (17.1 %); 81-100 years: 5/27 (18.5 %); p < 0.0001). The EGFR mutation was detected in 804/2107 (38.2 %) non-smoking women versus 125/806 (15.5 %) non-smoking men (p < 0.0001), while the corresponding figures for smokers were 60/273 (22.0 %) versus 147/2214 (6.6 %) (p < 0.0001). The obtained gender-related data differ from the estimates obtained in Asian studies; they indicate that increased prevalence of EGFR mutations in white females may not be entirely attributed to the low prevalence of smoking, but is likely to be related to gender factors per se. CONCLUSION: Biological causes of distinct age- and gender-related distribution of EGFR mutations in LC deserve further investigation.
INTRODUCTION: This study was aimed to evaluate distribution of epidermal growth factor receptor (EGFR) mutations in a large series of Russian lung cancer (LC) patients. METHODS: 10,607 LC samples were considered for EGFR analysis; EGFR status was successfully determined in 10,426 cases (98.3 %), indicating relatively low failure rate. RESULTS:EGFR mutations (ex19del and L858R) were detected in 1759/8716 (20.2 %) adenocarcinomas, 28/669 (4.2 %) squamous cell carcinomas (SCC) and 8/119 (6.7 %) large cell carcinomas. The occurrence of EGFR mutations in adenocarcinomas gradually increased with age, being attributed mainly to the increment of the L858R frequency in non-smokers (patients aged 18-30 years: 1/27 (3.7 %); 31-40 years: 5/98 (5.1 %); 41-50 years: 18/276 (6.5 %); 51-60 years: 102/944 (10.8 %); 61-70 years: 138/1011 (13.7 %); 71-80 years: 85/496 (17.1 %); 81-100 years: 5/27 (18.5 %); p < 0.0001). The EGFR mutation was detected in 804/2107 (38.2 %) non-smoking women versus 125/806 (15.5 %) non-smoking men (p < 0.0001), while the corresponding figures for smokers were 60/273 (22.0 %) versus 147/2214 (6.6 %) (p < 0.0001). The obtained gender-related data differ from the estimates obtained in Asian studies; they indicate that increased prevalence of EGFR mutations in white females may not be entirely attributed to the low prevalence of smoking, but is likely to be related to gender factors per se. CONCLUSION: Biological causes of distinct age- and gender-related distribution of EGFR mutations in LC deserve further investigation.
Authors: K Azuma; K Ota; A Kawahara; S Hattori; E Iwama; T Harada; K Matsumoto; K Takayama; S Takamori; M Kage; T Hoshino; Y Nakanishi; I Okamoto Journal: Ann Oncol Date: 2014-07-09 Impact factor: 32.976
Authors: Audrey Vallee; Christine Sagan; Anne-Gaelle Le Loupp; Kalyane Bach; Thomas Dejoie; Marc G Denis Journal: Int J Oncol Date: 2013-08-07 Impact factor: 5.650
Authors: Tatiana N Zamay; Galina S Zamay; Olga S Kolovskaya; Ruslan A Zukov; Marina M Petrova; Ana Gargaun; Maxim V Berezovski; Anna S Kichkailo Journal: Cancers (Basel) Date: 2017-11-13 Impact factor: 6.639